Table 1. Demographics of study cohort .... | American Society of Hematology

Table 1.

Demographics of study cohort

	MRD_pre assessed (N = 122)		MRD_post assessed (N = 139)		MRD_pre and MRD_post assessed (N = 111)
	N	%	N	%	N	%
Age (y)
Median (range)	44 (19-77)		43 (18-71)		44 (19-70)
18-39	50	41	60	43	44	40
40-59	46	38	50	36	43	39
60+	26	21	29	21	24	22
Sex
Male	68	56	79	57	62	56
Female	54	44	60	43	49	44
Race/ethnicity
Non-Hispanic White	54	44	65	47	48	43
Hispanic/Latino	33	27	38	27	30	27
African American	6	5	5	4	5	5
Asian	18	15	19	14	18	16
Other	11	9	12	9	10	9
Immunophenotype
B-cell	104	85	119	86	95	86
T-cell	18	15	20	14	16	14
Molecular subtype (B-cell ALL only)
Ph⁺∗	28	27	30	25	24	25
Ph-like†	13	13	13	11	13	14
MLLr/KMT2a rearrangement∗	5	5	6	5	5	5
Site of involvement
BM only	101	83	116	84	94	85
Extramedullary only	1	1	3	2	1	1
BM and extramedullary	20	16	20	14	16	14
Disease status at HCT
CR1	86	71	101	73	80	72
CR2⁺	32	26	33	24	27	24
Active	4	3	5	4	4	4
Donor type
Matched related donor	39	32	45	32	37	33
Unrelated donor
Matched unrelated donor	46	38	55	40	43	39
Mismatched unrelated donor	9	7	10	7	8	7
Haploidentical	11	9	11	8	9	8
Umbilical cord blood	17	14	18	13	14	13
Conditioning regimen
Myeloablative	102	84	115	83	91	82
Reduced intensity	20	16	24	17	20	18
2-y outcomes
Cumulative incidence of relapse	23	19	33	24	23	21
Nonrelapse mortality	22	18	14	10	13	12
Leukemia-specific mortality	12	10	20	14	12	11
Overall survival	88	72	105	76	86	77
Follow-up time from HCT (mo)
Median (range)	24 (12-24)		24 (12-24)		24 (12-24)

	MRD_pre assessed (N = 122)		MRD_post assessed (N = 139)		MRD_pre and MRD_post assessed (N = 111)
	N	%	N	%	N	%
Age (y)
Median (range)	44 (19-77)		43 (18-71)		44 (19-70)
18-39	50	41	60	43	44	40
40-59	46	38	50	36	43	39
60+	26	21	29	21	24	22
Sex
Male	68	56	79	57	62	56
Female	54	44	60	43	49	44
Race/ethnicity
Non-Hispanic White	54	44	65	47	48	43
Hispanic/Latino	33	27	38	27	30	27
African American	6	5	5	4	5	5
Asian	18	15	19	14	18	16
Other	11	9	12	9	10	9
Immunophenotype
B-cell	104	85	119	86	95	86
T-cell	18	15	20	14	16	14
Molecular subtype (B-cell ALL only)
Ph⁺∗	28	27	30	25	24	25
Ph-like†	13	13	13	11	13	14
MLLr/KMT2a rearrangement∗	5	5	6	5	5	5
Site of involvement
BM only	101	83	116	84	94	85
Extramedullary only	1	1	3	2	1	1
BM and extramedullary	20	16	20	14	16	14
Disease status at HCT
CR1	86	71	101	73	80	72
CR2⁺	32	26	33	24	27	24
Active	4	3	5	4	4	4
Donor type
Matched related donor	39	32	45	32	37	33
Unrelated donor
Matched unrelated donor	46	38	55	40	43	39
Mismatched unrelated donor	9	7	10	7	8	7
Haploidentical	11	9	11	8	9	8
Umbilical cord blood	17	14	18	13	14	13
Conditioning regimen
Myeloablative	102	84	115	83	91	82
Reduced intensity	20	16	24	17	20	18
2-y outcomes
Cumulative incidence of relapse	23	19	33	24	23	21
Nonrelapse mortality	22	18	14	10	13	12
Leukemia-specific mortality	12	10	20	14	12	11
Overall survival	88	72	105	76	86	77
Follow-up time from HCT (mo)
Median (range)	24 (12-24)		24 (12-24)		24 (12-24)

CR, complete remission.

Among those with B-cell ALL.

Among those with Ph-negative B-cell ALL.